Aratana Therapeutics Inc. (PETX) Trading Up 3.4%
Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price was up 3.4% on Wednesday . The stock traded as high as $6.70 and last traded at $6.67, with a volume of 205,500 shares trading hands. The stock had previously closed at $6.45.
Several equities analysts have weighed in on PETX shares. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a report on Tuesday, April 26th. Stifel Nicolaus dropped their target price on shares of Aratana Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, March 16th. Credit Suisse Group AG restated an “outperform” rating and set a $11.00 target price on shares of Aratana Therapeutics in a report on Tuesday, March 22nd. Craig Hallum dropped their target price on shares of Aratana Therapeutics from $11.00 to $7.00 and set a “hold” rating for the company in a report on Wednesday, March 16th. Finally, Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Thursday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.28.
The stock has a 50 day moving average of $6.55 and a 200-day moving average of $5.23. The company’s market cap is $243.54 million.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.10. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) earnings per share. Equities analysts anticipate that Aratana Therapeutics Inc. will post ($1.08) EPS for the current fiscal year.
In other Aratana Therapeutics news, insider Julia A. Stephanus sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total value of $187,500.00. Following the completion of the sale, the insider now directly owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Steven St sold 100,000 shares of the company’s stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $6.26, for a total transaction of $626,000.00. Following the completion of the sale, the chief executive officer now directly owns 717,793 shares of the company’s stock, valued at $4,493,384.18. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Aratana Therapeutics stock. Principal Financial Group Inc. raised its position in shares of Aratana Therapeutics Inc. (NASDAQ:PETX) by 46.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 400,000 shares of the biopharmaceutical company’s stock after buying an additional 127,300 shares during the period. Principal Financial Group Inc. owned approximately 1.14% of Aratana Therapeutics worth $2,232,000 as of its most recent SEC filing.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.